Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
- PMID: 29315431
- DOI: 10.1093/jnci/djx273
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Abstract
Background: In metastatic breast cancer, hormone and/or human epidermal growth factor receptor 2 (HER2)-targeted therapy decision-making is still largely based on tissue characteristics of the primary tumor. However, a change of estrogen receptor alpha (ERα), progesterone receptor (PR), and HER2 status in distant metastases has frequently been reported. The actual incidence of this phenomenon has been debated.
Methods: We performed a meta-analysis including 39 studies assessing receptor conversion from primary breast tumors to paired distant breast cancer metastases. We noted the direction of change (positive to negative or vice versa) and performed subgroup analyses for different thresholds for positivity, the type of test used to assess HER2 receptor status, and metastasis location-specific differences (two-sided tests).
Results: Overall, the incidence of receptor conversion varied largely between studies. For ERα, PR, and HER2, we found that random effects pooled positive to negative conversion percentages of 22.5% (95% confidence interval [CI] = 16.4% to 30.0%), 49.4% (95% CI = 40.5% to 58.2%), and 21.3% (95% CI = 14.3% to 30.5%), respectively. Negative to positive conversion percentages were 21.5% (95% CI = 18.1% to 25.5%), 15.9% (95% CI = 11.3% to 22.0%), and 9.5% (95% CI = 7.4% to 12.1%). Furthermore, ERα discordance was statistically significantly higher in the central nervous system and bone compared with liver metastases (20.8%, 95% CI = 15.0% to 28.0%, and 29.3%, 95% CI = 13.0% to 53.5%, vs 14.3%, 95% CI = 11.3% to 18.1, P = .008 and P < .001, respectively), and PR discordance was higher in bone (42.7%, 95% CI = 35.1% to 50.6%, P < .001) and liver metastases (47.0%, 95% CI = 41.0% to 53.0%, P < .001) compared with central nervous system metastases (23.3%, 95% CI = 16.0% to 32.6%).
Conclusions: Receptor conversion for ERα, PR, and HER2 occurs frequently in the course of disease progression in breast cancer. Large prospective studies assessing the impact of receptor conversion on treatment efficacy and survival are needed. Meanwhile, reassessing receptor status in metastases is strongly encouraged.
Comment in
-
Response to A. Matikas et al.J Natl Cancer Inst. 2018 Nov 1;110(11):1282-1283. doi: 10.1093/jnci/djy048. J Natl Cancer Inst. 2018. PMID: 29618030 No abstract available.
-
RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.J Natl Cancer Inst. 2018 Nov 1;110(11):1280-1281. doi: 10.1093/jnci/djy046. J Natl Cancer Inst. 2018. PMID: 29618043 No abstract available.
Similar articles
-
Receptor conversion in distant breast cancer metastases.Breast Cancer Res. 2010;12(5):R75. doi: 10.1186/bcr2645. Epub 2010 Sep 23. Breast Cancer Res. 2010. PMID: 20863372 Free PMC article.
-
Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient.Ann Oncol. 2013 Dec;24(12):3017-23. doi: 10.1093/annonc/mdt390. Epub 2013 Oct 10. Ann Oncol. 2013. PMID: 24114857
-
Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution.Mod Pathol. 2020 Dec;33(12):2499-2506. doi: 10.1038/s41379-020-0615-z. Epub 2020 Jul 3. Mod Pathol. 2020. PMID: 32620918
-
Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.Cancer Metastasis Rev. 2016 Sep;35(3):427-37. doi: 10.1007/s10555-016-9631-3. Cancer Metastasis Rev. 2016. PMID: 27405651 Review.
-
Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.Clin Breast Cancer. 2015 Oct;15(5):307-12. doi: 10.1016/j.clbc.2015.03.010. Epub 2015 Mar 25. Clin Breast Cancer. 2015. PMID: 25922284 Review.
Cited by
-
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival.Breast Cancer Res Treat. 2024 May 23. doi: 10.1007/s10549-024-07368-w. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38780889
-
Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors.PeerJ. 2024 May 15;12:e17377. doi: 10.7717/peerj.17377. eCollection 2024. PeerJ. 2024. PMID: 38766488 Free PMC article.
-
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program.NPJ Breast Cancer. 2024 Apr 24;10(1):31. doi: 10.1038/s41523-024-00637-3. NPJ Breast Cancer. 2024. PMID: 38658604 Free PMC article.
-
Tumor heterogeneity and clinically invisible micrometastases in metastatic breast cancer-a call for enhanced surveillance strategies.NPJ Precis Oncol. 2024 Mar 29;8(1):81. doi: 10.1038/s41698-024-00572-3. NPJ Precis Oncol. 2024. PMID: 38553598 Free PMC article.
-
Hormone receptor conversion in metastatic breast cancer.Rep Pract Oncol Radiother. 2024 Feb 16;28(6):746-755. doi: 10.5603/rpor.98730. eCollection 2023. Rep Pract Oncol Radiother. 2024. PMID: 38515821 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous